View in EDS

1417PPreliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations

Saved in:
Bibliographic Details
Title: 1417PPreliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations
Authors: Pilotto, S1 (AUTHOR), Grizzi, G1 (AUTHOR), Sperduti, I2 (AUTHOR), Simbolo, M3 (AUTHOR), Vicentini, C3 (AUTHOR), Caliò, A3 (AUTHOR), Caccese, M1 (AUTHOR), Mafficini, A3 (AUTHOR), Carbognin, L1 (AUTHOR), Corbo, V3 (AUTHOR)
Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p. 1 Chart.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdy292.039